Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 36Stomach Neoplasms 9Colonic Neoplasms 6Rectal Neoplasms 3Sarcoma 2Carcinoma, Hepatocellular 2Advanced Colorectal Carcinoma 2Unresectable Metastatic Colorectal Cancer 1Platinum Resistant Ovarian Cancer 1Patients With Advanced Metastatic Colorectal Cancer 1Pancreatic Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1NSCLC 1Metastatic Colorectal Adenocarcinoma 1Metastasis Colorectal Cancer 1Lung Neoplasms 1Locally Advanced Rectal Cancer 1Gastric/Gastroesophageal Junction Adenocarcinoma 1Gastric Cancer Adenocarcinoma Metastatic 1Fruquintinib 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Cancer Metastatic 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Adenocarcinoma 1Advanced Solid Tumors 1Advanced Pancreatic Carcinoma 1Advanced Gastric Cancer 1

Interventions

HMPL-013 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Unresectable Metastatic Colorectal Cancer × HMPL-013 × Clear all
NCT04866108 2022-08-18

A Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous Chemotherapy

Beijing Friendship Hospital

Phase 2 Unknown
49 enrolled
Gastrointestinal

Unresectable Metastatic Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡